

Patients with [leptomeningeal carcinomatosis](#) face a particularly grim prognosis. Current treatment consists of [intrathecal](#) delivery of [methotrexate](#) (MTX) or [cytosine arabinoside](#) (Ara-C) via [ventricular access device](#) ([Ommaya reservoir](#)) or [lumbar puncture](#). Yet despite these interventions, the median survival after diagnosis is only 4-7 months ¹⁾.

¹⁾

Chen TC, Napolitano GR, Adell F, Schönthal AH, Shachar Y. Development of the Metronomic Biofeedback Pump for leptomeningeal carcinomatosis: technical note. J Neurosurg. 2015 Aug;123(2):362-72. doi: 10.3171/2014.10.JNS14343. Epub 2015 May 8. PubMed PMID: 25955873.

From:

<https://neurosurgerywiki.com/wiki/> - **Neurosurgery Wiki**

Permanent link:

https://neurosurgerywiki.com/wiki/doku.php?id=cytosine_arabinoside

Last update: **2024/06/07 02:56**

